Bio-Techne director’s partner sells 1,976 shares
Bio-Techne Corp director Amy E. Herr reported an indirect sale of common stock through her significant other.
Rhea-AI Filing Summary
Bio-Techne Corp director Amy E. Herr reported an indirect sale of common stock through her significant other. On February 17, 2026, an account held by her significant other sold 1,976 shares of Bio-Techne common stock in an open-market transaction at a weighted average price of $59.105 per share, with individual trade prices ranging from $59.091 to $59.139.
After this sale, that indirect account held 200 shares of common stock. Separately, Herr holds 2,680 shares of common stock directly, along with various stock options and restricted stock units that vest on scheduled dates between 2025 and 2029, providing additional potential future equity exposure.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 1,976 shares
Net Sell
16 txns
Insider
Herr Amy E.
Role
Director
Sold
1,976 shs ($117K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,976 | $59.105 | $117K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 200 shares (Indirect, By significant other);
Stock Option (Right to Buy) — 6,192 contracts (Direct);
Stock Option (Right to Buy) — 20,919 contracts (Indirect, By significant other);
Restricted Stock Units — 1,447 contracts (Indirect, By significant other);
Common Stock — 2,680 shares (Direct)
Footnotes (13)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.091 to $59.1390, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
- F3. Fully vested.
- F4. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
- F5. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- F6. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F7. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
- F8. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F9. 118 restricted stock units vest on 8/15/2026.
- F10. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- F11. 38 restricted stock units vest on 2/3/2027 and 39 restricted stock units vest on 2/3/2028.
- F12. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
- F13. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
FAQ
What insider transaction did BIO-TECHNE (TECH) report for Amy E. Herr?
The filing shows an indirect sale of 1,976 Bio-Techne common shares by an account held by director Amy E. Herr’s significant other, executed in the open market at a weighted average price of $59.105 per share on February 17, 2026.
What equity awards for BIO-TECHNE (TECH) are described in Amy E. Herr’s Form 4?
The filing lists multiple stock options and restricted stock units. Options and units vest on specified dates between 2025 and 2029, including tranches that vest on August 15 and February 3 in several consecutive years, creating staged future equity vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
